| CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. A Davies, DL Simmons, G Hale, RA Harrison, H Tighe, PJ Lachmann, ... The Journal of experimental medicine 170 (3), 637-654, 1989 | 733 | 1989 |
| Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. S Meri, BP Morgan, A Davies, RH Daniels, MG Olavesen, H Waldmann, ... immunology 71 (1), 1, 1990 | 693 | 1990 |
| Systemic lupus erythematosus, complement deficiency, and apoptosis MC Pickering, M Botto, PR Taylor, PJ Lachmann, MJ Walport Advances in immunology 76, 227-324, 2001 | 617 | 2001 |
| Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well … GD Ross, JA Cain, PJ Lachmann Journal of immunology (Baltimore, Md.: 1950) 134 (5), 3307-3315, 1985 | 562 | 1985 |
| Complement technology PJ Lachmann, MJ Hobart, WP Aston Handbook of experimental immunology 1, 5A, 1978 | 452 | 1978 |
| AIDS—an immunologic reevaluation M Seligmann, L Chess, JL Fahey, AS Fauci, PJ Lachmann, J L'Age-Stehr, ... New England Journal of Medicine 311 (20), 1286-1292, 1984 | 383 | 1984 |
| Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. MG Wing, T Moreau, J Greenwood, RM Smith, G Hale, J Isaacs, ... The Journal of clinical investigation 98 (12), 2819-2826, 1996 | 361 | 1996 |
| The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐and antigen‐stimulated human peripheral … SM McHugh, IR Rifkin, J Deighton, AB Wilson, PJ Lachmann, ... Clinical & Experimental Immunology 99 (2), 160-167, 1995 | 361 | 1995 |
| The localization of in vivo bound complement in tissue sections PJ Lachmann, HJ Muller-Eberhard, HG Kunkel, F Paronetto The Journal of Experimental Medicine 115 (1), 63-82, 1962 | 343 | 1962 |
| Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and … GD Ross, WJ Yount, MJ Walport, JB Winfield, CJ Parker, CR Fuller, ... Journal of immunology (Baltimore, Md.: 1950) 135 (3), 2005-2014, 1985 | 339 | 1985 |
| Reactive lysis: The complement-mediated lysis of unsensitized cells: II. The characterization of activated reactor as C56 and the participation of C8 and C9 PJ Lachmann, RA Thompson The Journal of experimental medicine 131 (4), 643-657, 1970 | 327 | 1970 |
| Clinical aspects of immunology RRA Coombs, PGH Gell, PJ Lachmann Blackwell Scientific Publications, 1975 | 321 | 1975 |
| Specificity of membrane complement receptor type three (CR3) for ß-glucans GD Ross, JA Cain, BL Myones, SL Newman, PJ Lachmann Complement 4 (2), 61-74, 1987 | 309 | 1987 |
| Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell Y Takeuchi, FL Cosset, PJ Lachmann, H Okada, RA Weiss, MK Collins Journal of virology 68 (12), 8001-8007, 1994 | 308 | 1994 |
| The amplification loop of the complement pathways PJ Lachmann Advances in immunology 104, 115-149, 2009 | 273 | 2009 |
| The demonstration in human serum of “conglutinogen-activating factor” and its effect on the third component of complement PJ Lachmann, HJ Müller-Eberhard The Journal of Immunology 100 (4), 691-698, 1968 | 273 | 1968 |
| The physiological breakdown of the third component of human complement RA Harrison, PJ Lachmann Molecular immunology 17 (1), 9-20, 1980 | 256 | 1980 |
| Reactive lysis: the complement-mediated lysis of unsensitized cells: I. The characterization of the indicator factor and its identification as C7 RA Thompson, PJ Lachmann The Journal of Experimental Medicine 131 (4), 629-641, 1970 | 254 | 1970 |
| Bee venom immunotherapy induces a shift in cytokine responses from a TH‐2 to a TH‐1 dominant pattern: comparison of rush and conventional immunotherapy SM McHugh, J Deighton, AG Stewart, PJ Lachmann, PW Ewan Clinical & Experimental Allergy 25 (9), 828-838, 1995 | 251 | 1995 |
| Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. PJ Lachmann, MK Pangburn, RG Oldroyd The Journal of experimental medicine 156 (1), 205-216, 1982 | 251 | 1982 |
